Menu Search
Equities

IN8BIO, Inc.

6JH:BER

IN8BIO, Inc.

Actions
  • Price (EUR)0.304
  • Today's Change-0.012 / -3.80%
  • Shares traded--
  • 1 Year change-54.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 20:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

  • Revenue in USD (TTM)0.00
  • Net income in USD-31.88m
  • Incorporated2018
  • Employees31.00
  • Location
    IN8BIO, Inc.Empire State Building350 5Th Avenue, Suite 5330NEW YORK 10118United StatesUSA
  • Phone+1 (646) 600-6438
  • Fax+1 (302) 655-5049
  • Websitehttps://www.in8bio.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.